Understanding the Pathogenesis and Epidemiology of Vitiligo

In this episode titled, ‘Understanding the Pathogenesis and Epidemiology of Vitiligo’, David Rosmarin led the conversation about the following questions:

What autoimmune mechanism is responsible for melanocyte destruction in vitiligo and why is this a target for therapies?

Which immune signaling pathways plays a key role in the pathogenesis of vitiligo?

How do JAK inhibitors disrupt the immune signaling involved in vitiligo progression?

What is the epidemiology of vitiligo and which patient populations are most at risk?

At what age does vitiligo most commonly begin and how does it impact quality of life?

David Rosmarin highlighted that vitiligo is a Th1-mediated autoimmune disease driven by interferon gamma, which signals through the Janus kinase (JAK) pathway to destroy melanocytes. The discussion noted that while the disease affects all races and ages, roughly 80% of patients develop it before age 30, with a United States prevalence of just under 0.5%. Dr. Rosmarin also emphasized that vitiligo profoundly impacts quality of life, often leading to higher rates of anxiety, depression, and social withdrawal, particularly as patients transition into their teenage years.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, ‘Psychosocial Impacts and Traditional Treatment Modalities in Vitiligo’, panelists continue their discussion on vitiligo and highlight the significant psychosocial and cultural burdens of the disease alongside the limitations and applications of traditional topical therapies and phototherapy.